BGM Group names new chairman and co-CEO

BGM Group Ltd reports that Chen Xin resigned as Chairman of the Board and Co-Chief Executive Officer, effective July 30, 2026, citing personal reasons and stating that his departure is not due to any dispute or disagreement with the company or its board.

Rhea-AI Filing Summary

BGM Group Ltd reports that Chen Xin resigned as Chairman of the Board and Co-Chief Executive Officer, effective July 30, 2026, citing personal reasons and stating that his departure is not due to any dispute or disagreement with the company or its board.

Effective the same date, the board appointed Zhanchang Xin, Chen Xin’s father, as Chairman. He has over 35 years of pharmaceutical research and engineering experience, has worked at Gansu Qilianshan Pharmaceutical Co. Ltd. for 41 years, served as its Chairman since August 2006, and holds pharmacy and MBA degrees. The company states he has had no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K in the past two years.

The board also appointed Hong Li as Co-Chief Executive Officer, effective July 30, 2026. She has extensive financial management and accounting experience, has been Chief Financial Officer of Gansu Qilianshan Pharmaceutical Co. Ltd. since August 2008, and has worked there for 35 years. She has no family relationship with any company director or executive officer and no transactions requiring Item 404(a) disclosure.

Filing Explained

Chen Xin resigned as BGM Group’s Chairman and Co-Chief Executive Officer effective July 30, 2026. The board’s appointments of Zhanchang Xin as Chairman and Hong Li as Co-Chief Executive Officer therefore put the disclosed leadership transition into effect.

Key Figures

Effective date of leadership changes: July 30, 2026 Zhanchang Xin industry experience: Over 35 years Zhanchang Xin tenure at Gansu Qilianshan: 41 years +3 more

6 metrics

Effective date of leadership changes July 30, 2026 Date Chen Xin’s resignation and the new appointments became effective

Zhanchang Xin industry experience Over 35 years Research and engineering in the pharmaceutical industry

Zhanchang Xin tenure at Gansu Qilianshan 41 years Years worked at Gansu Qilianshan Pharmaceutical Co. Ltd.

Chairman role at Gansu Qilianshan Since August 2006 Start of Zhanchang Xin’s chairman role at Gansu Qilianshan

Hong Li tenure at Gansu Qilianshan 35 years Years Hong Li has worked at Gansu Qilianshan Pharmaceutical Co. Ltd.

Hong Li CFO role start Since August 2008 Start of Hong Li’s Chief Financial Officer position at Gansu Qilianshan

Key Terms

foreign private issuer, Co-Chief Executive Officer, Regulation S-K, principal executive office

4 terms

foreign private issuer regulatory

"Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Co-Chief Executive Officer financial

"resignation letter of Mr. Chen Xin from his position as the Chairman of the Board and Co-Chief Executive Officer"

Regulation S-K regulatory

"would require disclosure under Item 404(a) of Regulation S-K"

A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.

principal executive office regulatory

"(Address of principal executive office)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership changes did BGM (BGM) announce on July 30, 2026?

BGM Group Ltd announced that Chen Xin resigned as Chairman and Co-Chief Executive Officer, effective July 30, 2026. The board appointed Zhanchang Xin as Chairman and Hong Li as Co-Chief Executive Officer on the same effective date.

Why did Chen Xin resign from BGM (BGM) and was there any dispute?

BGM Group Ltd states that Chen Xin resigned as Chairman and Co-Chief Executive Officer for personal reasons. The company specifically notes that his resignation was not due to any dispute or disagreement with the company or its board of directors.

Who is the new Chairman of BGM (BGM) and what is his background?

The board appointed Zhanchang Xin as Chairman effective July 30, 2026. He has over 35 years of pharmaceutical R&D and engineering experience, has worked at Gansu Qilianshan Pharmaceutical for 41 years, and has served as its Chairman since August 2006.

What is Hong Li’s role at BGM (BGM) and her professional experience?

Hong Li was appointed Co-Chief Executive Officer effective July 30, 2026. She has extensive financial management and accounting experience, has served as Chief Financial Officer of Gansu Qilianshan Pharmaceutical since August 2008, and has worked there for 35 years.

Are there family or related-party relationships in BGM’s (BGM) new leadership?

Zhanchang Xin, the new Chairman, is the father of Chen Xin. BGM states he has had no transactions requiring Item 404(a) disclosure. Hong Li has no family relationship with any director or executive officer and no such related-party transactions.

What educational qualifications do BGM’s (BGM) new leaders hold?

Zhanchang Xin holds a bachelor’s degree in pharmacy from Lanzhou University (June 1986) and an MBA from Beijing Technology and Business University (December 2001). Hong Li earned a bachelor’s degree in financial management from Gansu Open University.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/30/2026 - 04:15 PM Accepted by SEC EDGAR 07/30/2026 - 04:15 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 001-39805

BGM Group Ltd

No.152 Hongliang East 1st Street, No. 1703,

Tianfu New District, Chengdu, 610200,

People’s Republic of China

+86-028-64775180

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Change of Directors

Departure of Chairman of the Board of Directors and Co-Chief Executive Officer

On July 29, 2026, the board of directors (the “Board”) of BGM Group Ltd (the “Company”) received the resignation letter of Mr. Chen Xin from his position as the Chairman of the Board and Co-Chief Executive Officer of the Company, effective from July 30, 2026.

Mr. Chen Xin’ s resignation was due to his personal reasons and not as the result of any dispute or disagreement with the Company or the Board.

Appointment of New Chairman of the Board of Directors and Co-Chief Executive Officer

Effective from July 30, 2026, the Board appointed Mr. Zhanchang Xin as the Chairman of the Board of the Company.

The biographical information of Mr. Zhanchang Xin is set forth below:

Mr. Zhanchang Xin has extensive experience in corporate management and the pharmaceutical industry. Since August 2006, Mr. Xin has served as the Chairman of the Board of Gansu Qilianshan Pharmaceutical Co. Ltd. Mr. Xin has over 35 years of research and engineering in the pharmaceutical industry. He has worked for Gansu Qilianshan Pharmaceutical Co. Ltd. for 41 years and has published pharmaceutical research papers in Chinese medical journals such as “China Medical Industry Journal” and “Gansu Pharmaceutical”. In June 1986, Mr. Xin received a bachelor’s degree in pharmacy from the School of Medicine at Lanzhou University. Mr. Xin received his master’s degree in business administration from Beijing Technology and Business University in December 2001.

Mr. Zhanchang Xin is the father of Mr. Chen Xin and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.

Effective from July 30, 2026, the Board appointed Ms. Hong Li (“Ms. Li”) as the Co-Chief Executive Officer of the Company.

The biographical information of Ms. Li is set forth below:

Ms. Li has extensive experience in financial management and accounting. Since August 2008, Ms. Li has served as the Chief Financial Officer of Gansu Qilianshan Pharmaceutical Co. Ltd. She has worked for Gansu Qilianshan Pharmaceutical Co. Ltd. for 35 years. Ms. Li received her bachelor’s degree in financial management from Gansu Open University.

Ms. Li does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 30, 2026

BGM GROUP LTD.
By:	/s/ Huandi Zhao
Name:	Huandi Zhao
Title:	Co-Chief Executive Officer and Director (Principal Executive Officer)